Blood Glucose Monitoring Systems Market is Anticipated to Witness CAGR of 7.72% and is Speculated to Reach USD 18.89 Billion by 2026, Asserts DelveInsight
The Global Blood Glucose Monitoring Systems market is expected to witness significant growth owing to the growing diabetes prevalence among the population across the globe, rising product approvals pertaining to Blood Glucose Monitoring Systems, rising technological advancements, and recent launches in the Blood Glucose Monitoring Systems market landscape.
Las Vegas, USA, Feb. 02, 2022 (GLOBE NEWSWIRE) -- Blood Glucose Monitoring Systems Market is Anticipated to Witness CAGR of 7.72% and is Speculated to Reach USD 18.89 Billion by 2026, Asserts DelveInsight
The Global Blood Glucose Monitoring Systems market is expected to witness significant growth owing to the growing diabetes prevalence among the population across the globe, rising product approvals pertaining to Blood Glucose Monitoring Systems, rising technological advancements, and recent launches in the Blood Glucose Monitoring Systems market landscape.
DelveInsight's Blood Glucose Monitoring Systems Market Insights and Forecast report provide the current and forecast Blood Glucose Monitoring Systems, upcoming innovation in the devices, individual market shares of the devices, challenges, drivers and barriers, market trends, and key competitors in the Blood Glucose Monitoring Device.
Some of the essential takeaways from the Blood Glucose Monitoring Systems Market report:
- According to DelveInsight analysis, North America is expected to dominate the overall Blood Glucose Monitoring Systems Market during the forecasted period.
- Key pharma players working proactively in the Blood Glucose Monitoring Systems include Medtronic, Abbott, F. Hoffmann-La Roche Ltd, LifeScan IP Holdings (Johnson & Johnson), Dexcom Inc., ARKRAY, Inc., Senseonics, WaveForm Technologies, Inc., B. Braun Melsungen AG, Ascensia Diabetes Care Holdings AG., Ypsomed, i-SENS, Inc., Intuity Medical, Inc., ACON Laboratories, Inc., Prodigy Diabetes Care, LLC, Sinocare, Rossmax International Ltd., A. Menarini Diagnostics s.r.l, Bionime Corporation., MEDISANA GMBH, Nemaura., and others.
- As per DelveInsight estimates, Global Blood Glucose Monitoring Systems was valued at USD 12.12 billion in 2020 and is anticipated to grow at a tremendous CAGR of 7.72% during the forecast period from 2021 to 2026 and is also expected to reach USD 18.89 billion by 2026.
- In November 2021, Intuity Medical launched the POGO Automatic Blood Glucose Monitoring System for diabetes patients in the US.
- On August 24, 2021, Smart Meter, the leader in cellular-connected remote patient monitoring (RPM) devices, data, and services, announced the availability of its iGlucose monitor for managing gestational diabetes.
- On July 27, 2021, Terumo launched the Dexcom G6 Continuous Glucose Monitoring (CGM) System in Japan, which is manufactured by Dexcom, Inc.
- In November 2020, Abbott, launched the FreeStyle Blood Glucose Monitor for adults and children (above the age of four) living with diabetes in India and women with gestational diabetes (diabetes during pregnancy).
- On February 19, 2020, DexCom, Inc. and Insulet Corporation entered into a commercialization agreement to combine current and future Dexcom Continuous Glucose Monitoring Systems (CGM) with Insulet’s trusted tubeless insulin delivery Pod into the Omnipod Horizon™ System for automated insulin delivery, currently in the pivotal trial.
- On February 11, 2020, Senseonics Holdings, Inc., a medical technology company focused on the development of the Implantable Continuous Glucose Monitoring (CGM) system entered into an agreement with Companion Medical to integrate Eversense® CGM System real-time glucose data with the Companion Medical InPen™ smart system for insulin delivery.
- The escalating demand for Blood Glucose Monitoring Systems is predominantly attributed to the increasing diabetes prevalence among the population across the globe and the growing burden of the geriatric population who are susceptible to developing hyperglycemia.
To pick on the latest highlights related to Blood Glucose Monitoring Systems get the snapshot of the key highlights entailed in the Blood Glucose Monitoring Systems Market report.
Blood Glucose Monitoring Systems Overview
Blood Glucose Monitoring Systems are used in health care settings to measure/monitor the amount glucose level or as a home glucose monitor to check the amount of glucose level in the blood. There are two types of Blood Glucose Monitors available in the market – self–monitoring of Blood Glucose Monitoring Systems and Continuous Glucose Monitoring Systems that can assist in diabetes diagnosis.
Interested in knowing how the Blood Glucose Monitoring Systems will be growing by 2026? Click to get a snapshot of Blood Glucose Monitoring Systems Analysis
Blood Glucose Monitoring Systems Market Insight
Geographically, the Global Blood Glucose Monitoring Systems market is studied for North America, Europe, Asia-Pacific, and the Rest of the World. In terms of revenue share, North America tends to lead the Global Blood Glucose Monitoring Systems market in the present scenario, and is expected that it will continue to remain superior during the forecast period. However, the domination exhibited by North America will be conspicuously challenged by the European market. This domination is attributed due to several factors such as the rising burden of the diabetic population in the American region, in addition, the increasing Obesity prevalence accounts for 80 to 85% of the risk of developing type 2 diabetes, rising adoption of technologically advanced Blood Glucose Monitoring devices, and the presence of all major key players in the North American Market.
For instance, on February 19, 2020, Abbott and Insulet Corporation partnered to integrate Abbott's world-leading continuous glucose-sensing technology and glucose readings with Insulet's next-generation tubeless system, the Omnipod Horizon™ Automated Insulin Delivery (AID) System (Omnipod Horizon System), to offer personalized automated insulin delivery and care for people living with signs of diabetes.
In addition to that, on April 05, 2019, WaveForm Technologies, Inc. a wholly-owned subsidiary of WaveForm Diabetes and developer of novel products for Continuous Glucose Monitoring which can help decrease the risk of hyperglycemia, entered into a partnership with A. Menarini Diagnostics S.r.l. to commercialize the WaveForm Technologies Continuous Glucose Monitor (CGM). Also, in the year 2019, Medtronic partnered with Handok to market and distribute Medtronic's Guardian Connect and iPro 2 continuous Blood Glucose Monitoring Systems in South Korea.
Learn more about the Blood Glucose Monitoring Systems Landscape @ Blood Glucose Monitoring Systems Assessment
Blood Glucose Monitoring Systems Market Dynamics
The major factors responsible for the growing demand of Blood Glucose Monitoring Systems are the growing diabetes prevalence among the worldwide population, technological advancement in the product portfolio, growing geriatric population, and rising government initiatives to raise awareness regarding proper diabetes management. In addition to that, improved healthcare infrastructure, rigorous glucose monitoring product approvals and launches, and increasing disposable income are also anticipated to boost the Blood Glucose Monitoring Systems market in the coming years.
On the contrary, the Blood Glucose Monitoring Systems market observed a period of stagnant growth owing to the outbreak of COVID-19. Due to the COVID-19 pandemic situation, all the other forms of elective procedures were temporarily stopped in contrast to the COVID-19 affected patients that were given utmost priority. Other factors such as lockdown restrictions, patient reluctance to visit the hospitals and clinics, logistical restrictions, and the closing down of manufacturing facilities have further impacted the Blood Glucose Monitoring Systems market.
To gain a better understanding of the COVID-19 impact on Blood Glucose Monitoring Devices, get a snapshot of the Blood Glucose Monitoring Systems Market Analysis
Scope of the Blood Glucose Monitoring Systems Report
- Coverage: Global
- Study Period: 2021-2026
- Market Segmentation By Product Type - Self-Monitoring of Blood Glucose Systems and Continuous Glucose Monitoring Systems
- Market Segmentation By Modality - Wearable Blood Glucose Monitors and Non-Wearable Blood Glucose Monitors
- Market Segmentation By End-User- Hospitals, Home Care Settings, and Others
- Market Segmentation By Geography - North America, Europe, Asia-Pacific, and Rest of World
- Key Blood Glucose Monitoring Systems Companies - Medtronic, Abbott, F. Hoffmann-La Roche Ltd, LifeScan IP Holdings (Johnson & Johnson), Dexcom Inc., ARKRAY, Inc., Senseonics, WaveForm Technologies, Inc., B. Braun Melsungen AG, Ascensia Diabetes Care Holdings AG., Ypsomed, i-SENS, Inc., Intuity Medical, Inc., ACON Laboratories, Inc., Prodigy Diabetes Care, LLC, Sinocare, Rossmax International Ltd., A. Menarini Diagnostics s.r.l, Bionime Corporation., MEDISANA GMBH, Nemaura., and others.
- Porter’s Five Forces Analysis
- Product Profiles
- Case Studies
- KOL's Views
- Analyst's View
Delveinsight Analysis: The Blood Glucose Monitoring Systems market is expected to grow at a CAGR of 7.72% and will reach USD 18.89 billion by 2026.
Know more about which MedTech player is set to emerge as the trendsetter @ Blood Glucose Monitoring Systems Market Landscape Analysis
Table of Contents
| 1 | Blood Glucose Monitoring Systems Report Introduction |
| 2 | Blood Glucose Monitoring Systems Executive summary |
| 3 | Regulatory and Patent Analysis |
| 4 | Blood Glucose Monitoring Systems Key Factors Analysis |
| 5 | Blood Glucose Monitoring Systems Porter’s Five Forces Analysis |
| 6 | COVID-19 Impact Analysis on Blood Glucose Monitoring Systems Market |
| 7 | Blood Glucose Monitoring Systems Market Layout |
| 8 | Blood Glucose Monitoring Systems Global Company Share Analysis – Key 3-5 Companies |
| 9 | Blood Glucose Monitoring Systems Company and Product Profiles |
|
9.1 Medtronic 9.2 Abbott 9.3 F. Hoffmann-La Roche Ltd 9.4 LifeScan IP Holdings (Johnson & Johnson) 9.5 Dexcom Inc. 9.6 ARKRAY 9.7 Senseonics 9.8 WaveForm Technologies, Inc. 9.9 B. Braun Melsungen AG 9.10 Ascensia Diabetes Care Holdings AG. 9.11 Ypsomed 9.12 i-SENS, Inc. 9.13 Intuity Medical, Inc. 9.14 ACON Laboratories, Inc 9.15 Prodigy Diabetes Care, LLC 9.16 Sinocare 9.17 Rossmax International Ltd. 9.18 Menarini Diagnostics s.r.l 9.19 Bionime Corporation 9.20 Nemaura |
|
| 10 | Project Approach |
| 11 | KOL Views |
| 12 | DelveInsight Capabilities |
| 13 | Disclaimer |
| 14 | About DelveInsight |
Learn more about the report offerings @ Blood Glucose Monitoring Systems Market Outlook
Related Reports
Chronic Pain associated with Painful Diabetic Neuropathy Market
DelveInsight’s ‘Chronic Pain associated with Painful Diabetic Neuropathy- Market Insight, Competitive Landscape and Market Forecast, 2026’ report delivers an in-depth understanding of Chronic Pain associated with Painful Diabetic Neuropathy covering the market trends, market drivers, market barriers and key companies involved such as Janssen Pharmaceuticals, Grunethal, Pfizer, Eli Lilly, Shionogi, Ono pharmaceuticals, Fremslife S.r.l, Helixmith, Aptinyx, Regenacy Pharmaceuticals, Novaremed, Nevro Corp, Erchonia Corporation, and others.
Injectable Drug Delivery Devices Market
Global Injectable Drug Delivery Devices Market was valued at USD 17.65 billion in 2020, growing at a CAGR of 11.25% during the forecast period from 2021 to 2026, to reach USD 33.37 billion by 2026. The report delivers an in-depth understanding of Injectable Drug Delivery Devices and the historical and forecasted market trends, market drivers, market barriers and key companies involved such as Eli Lilly and Company, Biocon, Becton, Dickinson & Company, West Pharmaceutical Services, Johnson & Johnson, Antares Pharma, AbbVie Inc, Pfizer Inc, Mylan N.V. and others.
DelveInsight’s ‘Smart Insulin Pens Market Insights, Competitive Landscape and Market Forecast-2026’ report delivers an in-depth understanding of Smart Insulin Pens and the historical and forecasted Smart Insulin Pens market trends, market drivers, market barriers and key companies involved such as Novo Nordisk, DiabNext, InsulCloud, Medtronic, Companion Medical, Biocorp, Bigfoot Medical, Emperra GmbH E-Health Technologies, and others.
Insulin Delivery Devices Market
Insulin Delivery Devices Market is anticipated to expand at a significant CAGR forecast till 2026 due to rising prevalence of diabetes across the globe. The report delivers an in-depth understanding of Insulin Delivery Devices and the historical and forecastedInsulin Delivery Devices market trends, market drivers, market barriers and key companies involved such as Biocon Ltd., Eli Lilly and Company, Insulet Corporation, Abbott, Terumo, CeQur, EOFLOW CO., LTD, European Pharma Group BV, Roche, Sanofi, Hindustan Syringes & Medical Devices Ltd, Ocean (Hangzhou) Medical Technology Co Ltd, Owen Mumford, and others.
Heart Pump Devices Market By Product, By Type, By Therapy, By End-User and By Geography is expected to grow at a steady CAGR. The report delivers an in-depth understanding of Heart Pump Devices and the historical and forecasted Heart Pump Devices market trends, market drivers, market barriers and key companies involved such as Abbott Laboratories, Abiomed, Teleflex Incorporated, SynCardia Systems, St. Jude Medical Inc, CARMAT, CorWave SA, Medtronic Inc, Terumo Heart.
Abnormal Glucose Tolerance Pipeline
DelveInsight’s, “Abnormal Glucose Tolerance Pipeline Insight, 2022,” report provides comprehensive insights about 5+ companies and 5+ pipeline drugs in the Abnormal Glucose Tolerance pipeline landscape. It covers the pipeline drug profiles, including clinical, non-clinical stage products and key companies involved such as REMD Biotherapeutics, Haisco Pharmaceutical Group Co., Ltd, Novo Nordisk A/S, Caelus Pharmaceuticals BV, and others.
DelveInsight’s, “Diabetes Pipeline Insights, 2022,” report provides comprehensive insights about 200+ companies and 200+ pipeline drugs in the Diabetes pipeline landscape. It covers the pipeline drug profiles, including clinical, non-clinical stage products and key companies involved such as Janssen Biotech, Zealand Pharma, Provention Bio, BioRestorative Therapies, Elevian, Kamada, Adocia, Oramed Pharmaceuticals, ImCyse, Histogen, Novo Nordisk, Enthera, and many more.
Interested to know more about the breakthrough happenings? Take a look at the posts below
- Evolution in Diabetes Management
- New Approaches and Evolutions to Reshape the Diabetes Management and Care
- Understanding The Increasing Prevalence Of Diabetes And Its Complications
About DelveInsight
DelveInsight is a leading Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. Get hassle-free access to all the healthcare and pharma market research reports through our subscription-based platform PharmDelve.
For more insights, visit Pharma, Healthcare, and Biotech News
Contact Us Shruti Thakur info@delveinsight.com +1(919)321-6187 www.delveinsight.com
